The effectiveness of cannabidiol in the treatment of anxiety disorders: An integrative literature review
DOI:
https://doi.org/10.33448/rsd-v13i2.45015Keywords:
Cannabidiol; Anxiety disorders; Therapeutics.Abstract
The objective was to report the effectiveness of the use of cannabidiol (CBD) in the treatment of anxiety disorders, as neuroimaging investigations in humans indicate that its action occurs in limbic brain areas, associated with anxiety. The lack of control over the doses and amount of cannabidiol used was analyzed to understand its mechanism in patients with anxiety. It is an integrative review study, collecting articles from the following platforms: Latin American and Caribbean Literature in Health Sciences (LILACS) and U.S. National Library of Medicine (PUBMED). To maintain the theme and support the article, the descriptors “cannabidiol”, “cannabidiol”, “treatment”, “anxiety disorders”, “anxiety disorders” and “CBD” were used. As inclusion criteria: published articles in the last 5 years, free access and as exclusion criteria therapy studies combined with tetrahydrocannabinol (THC) and animal analysis. The therapeutic potential of cannabidiol in the treatment of anxiety was observed with a favorable safety profile; action in facilitating extinction of fear and reduction of present fearful behaviors; in addition to oral CBD administered in a corn oil formula without the bioconversion of tetrahydrocannabinol(THC), contrary to recent studies. It is concluded that cannabidiol acts as a modulator of inflammatory processes in addition to reducing oxidative stress, emerging as a less harmful alternative compared to conventional treatments for anxiety disorder, however its use in the treatment of anxiety disorder still requires more research with a more cautious approach.
References
Batalla, A., Bos, J., Postma, A., & Bossong, M. G. (2021). The Impact of Cannabidiol on Human Brain Function: A Systematic Review. Frontiers in pharmacology, 11, 618184. https://doi.org/10.3389/fphar.2020.618184
Bloomfield, M. A. P., Yamamori, Y., Hindocha, C., Jones, A. P. M., Yim, J. L. L., Walker, H. R., Statton, B., Wall, M. B., Lees, R. H., Howes, O. D., Curran, V. H., Roiser, J. P., & Freeman, T. P. (2022). The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study. Psychopharmacology, 239(5), 1539–1549. https://doi.org/10.1007/s00213-022-06070-3
Bolsoni, L. M., Crippa, J. A. S., Hallak, J. E. C., Guimarães, F. S., & Zuardi, A. W. (2022). The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event. Revista brasileira de psiquiatria. 44(3), 298–307. https://doi.org/10.1590/1516-4446-2021-2317
Bolsoni, L. M., da Silva, T. D. A., Quintana, S. M., de Castro, M., Crippa, J. A., & Zuardi, A. W. (2019). Changes in Cortisol Awakening Response Before and After Development of Posttraumatic Stress Disorder, Which Cannot be Avoided with Use of Cannabidiol: A Case Report. The Permanente journal, 23, 18.300. https://doi.org/10.7812/TPP/18.300
Crippa, J. A. S., Zuardi, A. W., Hallak, J. E. C., Miyazawa, B., Bernardo, S. A., Donaduzzi, C. M., Guzzi, S., Favreto, W. A. J., Campos, A., Queiroz, M. E. C., Guimarães, F. S., da Rosa Zimmermann, P. M., Rechia, L. M., Jose Tondo Filho, V., & Brum Junior, L. (2020). Oral Cannabidiol Does Not Convert to Δ8-THC or Δ9-THC in Humans: A Pharmacokinetic Study in Healthy Subjects. Cannabis and cannabinoid research, 5(1), 89–98. https://doi.org/10.1089/can.2019.0024
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020). Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Frontiers in psychiatry, 11, 595584. https://doi.org/10.3389/fpsyt.2020.595584
Kirkland, A. E., Fadus, M. C., Gruber, S. A., Gray, K. M., Wilens, T. E., & Squeglia, L. M. (2022). A scoping review of the use of cannabidiol in psychiatric disorders. Psychiatry research, 308, 114347. https://doi.org/10.1016/j.psychres.2021.114347
Kwee, C. M., Baas, J. M., van der Flier, F. E., Groenink, L., Duits, P., Eikelenboom, M., van der Veen, D. C., Moerbeek, M., Batelaan, N. M., van Balkom, A. J., & Cath, D. C. (2022). Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 59, 58–67. https://doi.org/10.1016/j.euroneuro.2022.04.003
Leen-Feldner, E. W., Bynion, T. M., Gournay, R., Bonn-Miller, M. O., & Feldner, M. T. (2021). Practical considerations for testing the effects of cannabidiol on human anxiety. Journal of anxiety disorders, 82, 102429. https://doi.org/10.1016/j.janxdis.2021.102429
Linares, I. M., Zuardi, A. W., Pereira, L. C., Queiroz, R. H., Mechoulam, R., Guimarães, F. S., & Crippa, J. A. (2019). Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Revista brasileira de psiquiatria, 41(1), 9–14. https://doi.org/10.1590/1516-4446-2017-0015
Lookfong, N. A., Raup-Konsavage, W. M., & Silberman, Y. (2023). Potential Utility of Cannabidiol in Stress-Related Disorders. Cannabis and cannabinoid research, 8(2), 230–240. https://doi.org/10.1089/can.2022.0130
Lopes, K. C. da S. P., & Santos, W. L. dos. (2018). Transtorno de ansiedade. Revista de Iniciação Científica e Extensão, 1(1), 45–50. https://revistasfacesa.senaaires.com.br/index.php/iniciacao-cientifica/article/view/47
Martinez Naya, N., Kelly, J., Corna, G., Golino, M., Abbate, A., & Toldo, S. (2023). Molecular and Cellular Mechanisms of Action of Cannabidiol. Molecules (Basel, Switzerland), 28(16), 5980. https://doi.org/10.3390/molecules28165980
Masataka N. (2019). Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders. Frontiers in psychology, 10, 2466. https://doi.org/10.3389/fpsyg.2019.02466
Melas, P. A., Scherma, M., Fratta, W., Cifani, C., & Fadda, P. (2021). Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research. International journal of molecular sciences, 22(4), 1863. https://doi.org/10.3390/ijms22041863
Ortiz Rios, F. C., Dávila Ruiz, I. G., & Sacal Dumani, E. (2022). Cannabidiol as a personalized treatment for anxiety: clinical cases in Mexico. Drugs in context, 11, 2022-3-2. https://doi.org/10.7573/dic.2022-3-2
Ramos, E. M. C., Lima, K. R. S., Morais, A. C. F., Melo, L. M. F. de, Santos, J. R. dos, Santana, M. M. P. M. de, Santos, C. E. B. dos, Rodrigues, I. S. V., Moura, M. M. M. de, Costa, D. de J. M., Humia, B. V., Cruz, C. A. B., Santos, L. X. C. & Oliveira, R. I. S. 2022. O canabidiol no tratamento da epilepsia: Cannabidiol in the treatment of epilepsy. Brazilian Journal of Development. 8(10), 70103–70118. https://doi.org/10.34117/bjdv8n10-341
Saito, V. M., Wotjak, C. T., & Moreira, F. A. (2010). Exploração farmacológica do sistema endocanabinoide: novas perspectivas para o tratamento de transtornos de ansiedade e depressão? Brazilian Journal of Psychiatry, 32, 57–514. https://doi.org/10.1590/S1516-44462010000500004
Sousa, J. O. de, Vieira, V. B., Silva, G. F. da, Silveira, R. E. da, Santos, C. A. F. dos, Lima, L. F. de O., Bohnenberger, G., Camacho, B. A., Paiva, O. R., Massa, J. V. B., Campiol, N. L., & Maslinkiewicz, A. (2023). Potencial terapêutico dos canabinoides na ansiedade e depressão: uma revisão integrativa da literatura. Arquivos de Ciências da Saúde Da UNIPAR, 27(10), 5485–5497. https://doi.org/10.25110/arqsaude.v27i10.2023-002
Spezzia S. O emprego da cannabis medicinal no enfrentamento à doenças. Rev Ciênc Med. 2022;31:e225398. https://doi.org/10.24220/2318-0897v31e2022a5398
Van der Flier, F. E., Kwee, C. M. B., Cath, D. C., Batelaan, N. M., Groenink, L., Duits, P., van der Veen, D. C., van Balkom, A. J. L. M., & Baas, J. M. P. (2019). Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial. BMC psychiatry, 19(1), 69. https://doi.org/10.1186/s12888-019-2022- x
Zanellati, D. O Uso de Canabinoides no Tratamento da Ansiedade. Escola de ciências médicas, Farmacêuticas e biomédicas, PUC, 2021. repositorio.pucgoias.edu.br, https://repositorio.pucgoias.edu.br/jspui/handle/123456789/1905.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ketylla Lopes Tadaiesky Rodrigues; Leonardo Sales Correa do Nascimento; Lunna Martins Coelho; Maria Gabriela Perdigão Barros Monteiro; Vitória Carolina Pires de Castro; Isabela Guerreiro Diniz; Márcia Cristina Monteiro Guimarães
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
